CKD

Ardelyx to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 6, 2022
View, Therapy, Kidney, CKD, Kyowa Hakko Kirin, Metabolic acidosis, Fosun Pharma, Dialysis, Multimedia, Conference, Knight Therapeutics, Adult, Webcast, Event, Hyperkalemia, Patient, Pharmaceutical industry, Online shopping

To access the recording, please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com.

Key Points: 
  • To access the recording, please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com.
  • A replay of the webcast will be available on the Ardelyx website for 30 days following the conference.
  • Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs.
  • Ardelyx is developing XPHOZAH (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials.

Ketoanalogue for Kidney Disease Market to Rise at a CAGR of 6.5% during Forecast Period, notes TMR Study

Retrieved on: 
Tuesday, September 6, 2022
Kidney failure, Mortality, Acute kidney injury, Osteoarthritis, Disease, Lists of diseases, Chronic kidney disease, Incidence, CKD, Chronic obstructive pulmonary disease, Asthma, Dialysis, Kidney disease, Kidney, Hospital, Proteinuria, Dietary supplement, Prevalence, Hypertension, CAGR, Population, COPD, Diabetes, Patient, Pharmaceutical industry, Agriculture

The rising prevalence of kidney disease and growing use of ketoanalogue supplements in the treatment of renal disease are the two main factors likely to drive the global market for Ketoanalogue for Kidney Disease Market.

Key Points: 
  • The rising prevalence of kidney disease and growing use of ketoanalogue supplements in the treatment of renal disease are the two main factors likely to drive the global market for Ketoanalogue for Kidney Disease Market.
  • Global Ketoanalogue for Kidney Disease Market: Growth Drivers
    Depending on distribution channel, the global market for ketoanalogue for kidney disease is expected to be dominated by hospital pharmacies during the forecast timeframe.
  • The prevalence of kidney illness has increased in North America, which is why the region dominates the global market for ketoanalogue for kidney disease.
  • Global Ketoanalogue for Kidney Disease Market: Key Players
    Global Ketoanalogue for Kidney Disease Market: Segmentation

Montage Technology Delivers World's First Gen1 DDR5 Clock Driver Engineering Samples

Retrieved on: 
Thursday, September 1, 2022
RCD, Dram, Computer, Multimedia, DRAM, DDR5, Technology, CPU, PC, CKD, JEDEC, View, Computer data storage

For a long time, the clock driver functions have been integrated onto the register clock driver (RCD) device, which is used in the server platforms, rather than the PC computers.

Key Points: 
  • For a long time, the clock driver functions have been integrated onto the register clock driver (RCD) device, which is used in the server platforms, rather than the PC computers.
  • With the boost of the DDR5 data rate, the frequency of the clock signal becomes higher and higher, and the signal integrity issue of the clock becomes more and more challenging.
  • "We are very delighted to deliver our first DDR5CK01 engineering samples to the industry-leading DRAM vendors to support the development of the new-generation PC memory.
  • Montage will continue to foster technology innovation to provide complete and premier memory interface solutions for memory vendors," said Mr. Stephen Tai, President at Montage Technology.

Montage Technology Delivers World’s First Gen1 DDR5 Clock Driver Engineering Samples

Retrieved on: 
Thursday, September 1, 2022
Semiconductor, Hardware, Data Management, Consumer Electronics, Technology, RCD, DDR5, Technology, Computer, DRAM, CPU, CKD, Dram, Multimedia, JEDEC, PC, Computer data storage

Montage Technology, a leading data processing and interconnect IC design company, today announced that it is delivering the worlds first Gen1 DDR5 Clock Driver (CKD or DDR5CK01) samples to the top DRAM memory vendors for their development of memory modules used in new-generation desktop and notebook computers.

Key Points: 
  • Montage Technology, a leading data processing and interconnect IC design company, today announced that it is delivering the worlds first Gen1 DDR5 Clock Driver (CKD or DDR5CK01) samples to the top DRAM memory vendors for their development of memory modules used in new-generation desktop and notebook computers.
  • View the full release here: https://www.businesswire.com/news/home/20220901005361/en/
    Montage Technology's DDR5 Gen1 Clock Driver (DDR5CK01) (Photo: Business Wire)
    For a long time, the clock driver functions have been integrated onto the register clock driver (RCD) device, which is used in the server platforms, rather than the PC computers.
  • With the boost of the DDR5 data rate and the rising frequency of the clock signal, the signal integrity issue of the clock becomes increasingly challenging.
  • Montage will continue to foster technology innovation to provide complete and premier memory interface solutions for memory vendors, said Mr. Stephen Tai, President at Montage Technology.

ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations

Retrieved on: 
Wednesday, August 31, 2022
Mortality, Partnership, Doctor of Pharmacy, MPH, COVID-19, EMA, Memorial, Security (finance), Kidney, Technology, Renal replacement therapy, Research, Disease, SCS, Awareness, Chronic kidney disease, CKD, Humanitarian use licenses, Â, Investor relations, Diagnosis, U.S. Securities and Exchange Commission, IR, CFO, Corporate communication, GLOBE, University of the Sciences, Health, Nasdaq, FDA, Yale University, Immune system, Rutgers University, Memorial Sloan Kettering Cancer Center, Communication, Ernest Mario School of Pharmacy, Risk, Marketing, Hayward Medical Communications, Private Securities Litigation Reform Act, Growth, Pharmaceutical industry, Management, Public health, Pharmacy

WINSTON-SALEM, N. C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the appointment of Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations. Dr. Schulman, who will report to Chief Financial Officer James Coulston, joins ProKidney after leading investor relations and corporate communication efforts at a number of early and late-stage Nasdaq-listed biopharmaceutical companies focused on the development of therapies to treat diseases of the immune system and kidneys.

Key Points: 
  • WINSTON-SALEM, N. C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (ProKidney), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the appointment of Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations.
  • James Coulston, CFO of ProKidney, said: On behalf of our team, I am excited to welcome Glenn to ProKidney.
  • Prior to joining ProKidney, Dr. Schulman served as Vice President of Investor Relations at X4 Pharmaceuticals.
  • Previous to that, Dr. Schulman was Senior Vice President, Investor Relations and Corporate Communications at Aurinia Pharmaceuticals; Executive Director, Investor Relations and Corporate Communications at Achillion Pharmaceuticals; and Director of Investor Relations and Medical Communications at CuraGen Corporation.

Aria Pharmaceuticals Advances Pipeline with Six Provisional US Patents Filed Across Three Diseases

Retrieved on: 
Tuesday, August 30, 2022
Inflammation, Collagen, CEO, Program, United States Patent and Trademark Office, Symphony, Patent, Achievement, Disease, Pyroptosis, Chronic kidney disease, USPTO, CKD, NCE, TGF, Senior, Fibrosis, PALO, IPF, Risk, Lupus, Idiopathic pulmonary fibrosis, Patient, Pharmaceutical industry, Chemistry

PALO ALTO, Calif., Aug. 30, 2022 /PRNewswire/ -- Aria Pharmaceuticals, a pharmaceutical company focused on bringing first-in-class small molecules to market, announced that the company has successfully filed a total of six provisional patents with the United States Patent and Trademark Office (USPTO) for lead candidates in its lupus, idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD) research programs.

Key Points: 
  • A provisional patent application with the USPTO allows Aria Pharmaceuticals to establish intellectual property protection for its novel therapies on the filing date.
  • Aria was able to identify novel compounds and file for provisional patents within 12-15 months for each program.
  • Aria Pharmaceuticals has built a pipeline across 18 diseases utilizing its Symphony platform for complex diseases where new treatments are needed.
  • Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel small molecule therapies for complex and hard-to-treat diseases.

TRICIDA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA

Retrieved on: 
Saturday, August 27, 2022
Legal, Professional Services, NDA, Accelerated approval (FDA), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, Lists of schools in England, CKD, Serum, Food, FDA, Company, LLC, Review, KSF, Pharmaceutical industry

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF continues its investigation into Tricida, Inc. (NasdaqGS: TCDA).

Key Points: 
  • Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF continues its investigation into Tricida, Inc. (NasdaqGS: TCDA).
  • Finally, on February 25, 2021, the Company disclosed that the FDA had denied the appeal of its NDA denial.
  • KSFs investigation is focusing on whether Tricidas officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nations premier boutique securities litigation law firms.

Evergreen Nephrology celebrates 1 year anniversary and appointment of new board member

Retrieved on: 
Thursday, August 25, 2022
HIV disease progression rates, Nephrology, Technology, CKD, Board, Standard of care, Health, Kidney disease, Quality of life, MD, ESKD, Evergreen, Patient, Medicine

"I have found fulfillment throughout my healthcare career by focusing on people and purpose-- helping people thrive and serving a higher purpose together in community. My favorite way to do both has been through value-based care, which I have seen work best when patient-centered and physician-led.  I believe Evergreen Nephrology is doing exactly that in its approach to value-based kidney care, and I am excited to join your community and mission," said Charlie Choi, Evergreen Nephrology Board Member.

Key Points: 
  • NASHVILLE, Tenn., Aug. 25, 2022 /PRNewswire/ -- Evergreen Nephrology is proud to celebrate its one-year anniversary and the appointment of the newest board member, Charlie Choi, effective September 1, 2022.
  • Evergreen Nephrology partners with nephrologists in local markets to transform kidney care, and Evergreen believes that nephrologists are best positioned to lead this charge.
  • I believe Evergreen Nephrology is doing exactly that in its approach to value-based kidney care, and I am excited to join your community and mission," said Charlie Choi, Evergreen Nephrology Board Member.
  • We are confident that Charlie's input as a Board member will help propel Evergreen to the top," said Jeff Glaze, MD, Board Member at Evergreen Nephrology and President of the Evergreen Physicians Leadership Council.

Baxter Broadens Efforts to Increase Awareness, Education and Support of Kidney Health in Black Communities

Retrieved on: 
Thursday, August 25, 2022
Medical Supplies, Other Consumer, Diabetes, Health, Philanthropy, Medical Devices, Hospitals, Surgery, Fund Raising, Foundation, Consumer, ACT, Statistics, Partnership, NKF, African Americans, COVID-19, Link Community Development, Kidney failure, Health equity, Caregiver, NYSE, United States Department of Health and Human Services, Friends, Awareness, Kidney, Chronic kidney disease, Critical care, Culture, Person, Baxter International, Medtech, CKD, Overalls, GA, Organic, Commonwealth, National Kidney Foundation, LinkedIn, Altrusa International, Inc, Kidney disease, Baxter, Hospital, Community, Center, District, The, Centers for Disease Control and Prevention, Workplace, Prevalence, Twitter, United Kingdom, Woman, Health, Patient, Renewable energy, Pharmaceutical industry, Black, Link, Education, Facebook

Through these efforts and The Links programs, more than 51,000 community members received kidney health awareness and education resources.

Key Points: 
  • Through these efforts and The Links programs, more than 51,000 community members received kidney health awareness and education resources.
  • Those participants were able to meet with a physician onsite and receive practical tips and educational materials around kidney health.
  • A component of Baxters ACT: Activating Change Today initiative , the partnership with The Links includes the Black Kidney Awareness, Resources and Education (K.A.R.E.)
  • toolkit , a resource developed by The National Kidney Foundation of Illinois that focuses on the unique barriers facing the Black community.

Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on: 
Thursday, August 25, 2022
Research, Women, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, Oncology, Transfer, European Society for Medical Oncology, Ministry, Safety, HPV, Merck Sharp & Dohme Federal Credit Union, Human papillomavirus infection, KOSDAQ, Head, CKD, Judgement, Hope, Cervical cancer, Neck, Data analysis, DNA, International Money Transfers System Leader, Goal, Pembrolizumab, Immunotherapy, Therapy, DART, Oncology, Merck, Congress, Merck & Co., MFDS, Patient, Pharmaceutical industry, Vaccine, Food, Korean

We believe this could offer hope for a new immunotherapy treatment option to patients with recurrent/metastatic end-stage cervical cancer.

Key Points: 
  • We believe this could offer hope for a new immunotherapy treatment option to patients with recurrent/metastatic end-stage cervical cancer.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
  • Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics.
  • Genexine has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value.